Otitis media
Drug research and approvals for otitis media: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 22 studies of otitis media are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and the EU has 3 authorised medicines for it.
- Recruiting worldwide: 22
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 3
- Platelet-Rich Fibrin in Revision Cartilage TympanoplastyNCT07893418 · Not applicable · Bakirkoy Dr. Sadi Konuk Research and Training Hospital · starts Feb 15, 2026
- Towards Implementation of Universal Newborn Hearing Screening in KenyaNCT07879326 · Not applicable · University of Washington · starts Sep 24, 2026
- Comparative Effectiveness of Available Treatments for Sinus and Ear Infections in Children (Acute Otitis Media)NCT07730814 · Phase 4 · Nader Shaikh · starts Oct 1, 2026
- Parent-led Assessment and Recognition of AOM Using Digital Ear ImagingNCT07640568 · Not applicable · Turku University Hospital · starts Sep 1, 2026
- CLIKX® Tympanostomy Tube Delivery System for the Placement of Tympanostomy TubesNCT07625657 · Not applicable · ClinQure, Inc. · starts Jul 7, 2026
- Evaluation of the Medentum Diagnostik Platform for Pediatric ENT Conditions and AsthmaNCT07500532 · Not applicable · Medentum Innovations · starts Oct 1, 2025
- Impact of a Multimodal Intervention on Antibiotic Prescribing for Respiratory Infections in Primary CareNCT07359287 · Not applicable · University Hospital, Caen · starts Dec 1, 2025
- Safety and Efficacy of wSp Vaccine in Young ChildrenNCT07216430 · Phase 2 · Serum Life Science Europe GmbH · starts Sep 29, 2025
- Perspectives on Antibiotics and Tracking Symptoms in ChildrenNCT07093749 · Not applicable · Murdoch Childrens Research Institute · starts Sep 16, 2025
Approved 14
- AmoxicillinBacterial penicillin-binding protein inhibitor
- AzithromycinBacterial 70S ribosome inhibitor
- Clavulanic acidBacterial beta-lactamase TEM inhibitor
- CefdinirBacterial penicillin-binding protein inhibitor
- TrimethoprimBacterial dihydrofolate reductase inhibitor
- CefaclorBacterial penicillin-binding protein inhibitor
- Cefuroxime axetilBacterial penicillin-binding protein inhibitor
- Cefprozil anhydrous, (e)-Bacterial penicillin-binding protein inhibitor
- CephalexinBacterial penicillin-binding protein inhibitor
- CeftriaxoneBacterial penicillin-binding protein inhibitor
- CeftibutenBacterial penicillin-binding protein inhibitor
- CefiximeBacterial penicillin-binding protein inhibitor
- Cefpodoxime proxetilBacterial penicillin-binding protein inhibitor
- ClarithromycinBacterial 70S ribosome inhibitor
Phase 3 10
- MoxifloxacinTopoisomerase IV inhibitor
- Benzocaine
- CiprofloxacinBacterial DNA gyrase inhibitor
- TelithromycinBacterial 70S ribosome inhibitor
- DexamethasoneGlucocorticoid receptor agonist
- LevofloxacinDNA gyrase inhibitor
- OfloxacinBacterial DNA gyrase inhibitor
- Glycerin
- Xylitol
- Syrup
Phase 2 4
- SimethiconeAntifoaming agent
- FinafloxacinTopoisomerase IV inhibitor
- AntipyrineCyclooxygenase-1 inhibitor
- Faropenem medoxomilBacterial penicillin-binding protein inhibitor
Phase 1 or earlier 3
- TazobactamBacterial beta-lactamase TEM inhibitor
- PiperacillinBacterial penicillin-binding protein inhibitor
- PazufloxacinBacterial DNA gyrase inhibitor
How its trials ended
271 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 67 whose ending is known, 39% met their primary endpoint, 16% missed it and 45% stopped early.
- Completed, result not reported12646%
- Status unknown4416%
- Ongoing3413%
- Met its primary endpoint2610%
- Stopped: other or unclear187%
- Missed its primary endpoint114%
- Stopped: sponsor or business decision52%
- Stopped: enrollment or feasibility41%
- Stopped: lack of efficacy31%
| Dec 13, 2021 | VaxneuvancePneumococcal polysaccharide conjugate vaccine (adsorbed) | Merck Sharp & Dohme B.V. | EMA ↗ |
| Dec 9, 2009 | Prevenar 13Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) | Pfizer Europe MA EEIG | EMA ↗ |
| Mar 29, 2009 | SynflorixPneumococcal polysaccharide conjugate vaccine (adsorbed) | GlaxoSmithKline Biologicals S.A. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA